2021
DOI: 10.1016/j.adaj.2021.01.009
|View full text |Cite
|
Sign up to set email alerts
|

COVID-19 vaccination: science, politics and public health

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 3 publications
(3 reference statements)
0
2
0
Order By: Relevance
“…Currently, the most spectacular RNA-backbone biopharmaceuticals are those of already the US FDA approved optimized siRNAs, properly equipped with functional groups, with 2 -OMe modifications among others, allowing them to be efficiently stabilized and delivered, including patisiran (Onpattro ® , 2018) against polyneuropathy (TTR), givosiran (Givlaari ® , 2019) for acute hepatic porphyria (AHP), inclisiran (Leqvio ® , 2020), for the treatment of adults with hypercholesterolemia or mixed dyslipidemia, and lumasiran, sold under the brand name Oxlumo ® (2020), which is a siRNA medication for the treatment of primary hyperoxaluria type 1 (PH1) [10]. The second class of already the US FDA and EU EMA approved RNA biopharmaceuticals are mRNA vaccines that have been developed for use in combating coronavirus disease 2019 (COVID-19 pandemic) [11,12].…”
Section: -O-methylation (-Omementioning
confidence: 99%
“…Currently, the most spectacular RNA-backbone biopharmaceuticals are those of already the US FDA approved optimized siRNAs, properly equipped with functional groups, with 2 -OMe modifications among others, allowing them to be efficiently stabilized and delivered, including patisiran (Onpattro ® , 2018) against polyneuropathy (TTR), givosiran (Givlaari ® , 2019) for acute hepatic porphyria (AHP), inclisiran (Leqvio ® , 2020), for the treatment of adults with hypercholesterolemia or mixed dyslipidemia, and lumasiran, sold under the brand name Oxlumo ® (2020), which is a siRNA medication for the treatment of primary hyperoxaluria type 1 (PH1) [10]. The second class of already the US FDA and EU EMA approved RNA biopharmaceuticals are mRNA vaccines that have been developed for use in combating coronavirus disease 2019 (COVID-19 pandemic) [11,12].…”
Section: -O-methylation (-Omementioning
confidence: 99%
“…Since research has shown that some individuals are more likely to seek dental care (including for cosmetic reasons) compared with medical care, dental professionals need appropriate training so they can counsel their patients appropriately and even administer HPV and other vaccines, including COVID-19 (52). In fact, several states have approved providing vaccines in the dental setting, a view supported by the American Dental Association (53,54).…”
Section: Human Papillomavirus Virus (Hpv) Vaccinementioning
confidence: 99%